Abstract
To evaluate effectiveness and safety of rituximab (RTX) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in Japan. In this prospective observational study, all patients with MPA and GPA administered RTX were enrolled at each institution. During observation period of two years, data up to six months was analysed. Cox proportional hazards analysis was used to assess the factors associated with an outcome. Of the 75 patients who received RTX for remission induction therapy, 53 achieved remission by 6th month and 50 were in remission at 6th month. During therapy, 38 serious adverse events (SAE) were observed in 24 patients, 21 serious infections (SI) in 16 patients, and nine patients died. No factors were associated with remission; however, there was a significant difference between patients with and without remission in SAE (22.6 vs. 54.5 %), SI (11.3 vs. 45.4 %), and death (1.9 vs. 36.4 %). The hazard ratio (95 % CI) for SI was 3.49 (1.29-9.74) for patients aged ≥ 75 years and 3.53 (1.31-9.53) for pulmonary complications. Four patients maintained remission for 6 months. Effectiveness and safety of RTX for MPA and GPA for up to 6 months was demonstrated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.